Protalix Biotherapeutics Inc. (PLX) Attracts A Huge Investment By A Large Hedge Fund

Page 3 of 6 – SEC Filing

Item 1(a).	NAME OF ISSUER:
	The name of the issuer is Protalix BioTherapeutics, Inc. (the “Company“).

Item 1(b).	ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
	The Company’s principal executive offices are located at 2 Snunit Street, Science Park, POB 455, Carmiel 20100, Israel.

Item 2(a).	NAME OF PERSON FILING:
Item 2(b).	ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Item 2(c).	CITIZENSHIP:

	This statement is filed by:
		Highbridge Capital Management, LLC 40 West 57th Street, 32nd Floor New York, New York 10019 Citizenship: State of Delaware
	The foregoing person is hereinafter sometimes referred to as the “Reporting Person.”

Item 2(d).	TITLE OF CLASS OF SECURITIES:
	Common Stock, par value $0.001 per share (the “Common Stock“).

Item 2(e).	CUSIP NUMBER:
	74365A101

Item 3.

IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

	(a)	¨	Broker or dealer registered under Section 15 of the Act,
	(b)	¨	Bank as defined in Section 3(a)(6) of the Act,
	(c)	¨	Insurance Company as defined in Section 3(a)(19) of the Act,
	(d)	¨	Investment Company registered under Section 8 of the Investment Company Act of 1940,
	(e)	¨	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
	(f)	¨	Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
	(g)	¨	Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),

Follow Protalix Biotherapeutics Inc. (NYSEMKT:PLX)

Follow Protalix Biotherapeutics Inc. (NYSEMKT:PLX)

---

or

Subscribe with Google

We may use your email to send marketing emails about our services. Click here to read our privacy policy.